DC
BMRN icon

Davenport & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Davenport & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,063
Closed -$439K – 1056
2023
Q2 		$439K Buy
5,063
+306
+6% +$28.8K ﹤0.01% 776
2023
Q1 		$463K Sell
4,757
-1,700
-26% -$176K ﹤0.01% 740
2022
Q4 		$668K Buy
6,457
+305
+5% +$28.6K 0.01% 607
2022
Q3 		$522K Sell
6,152
-438
-7% -$39K ﹤0.01% 663
2022
Q2 		$546K Buy
6,590
+444
+7% +$35.4K ﹤0.01% 664
2022
Q1 		$474K Buy
6,146
+271
+5% +$22.7K ﹤0.01% 748
2021
Q4 		$519K Buy
+5,875
New +$485K ﹤0.01% 745
2021
Q1 		– Sell
-5,044
Closed -$442K – 806
2020
Q4 		$442K Sell
5,044
-85
-2% -$6.74K ﹤0.01% 557
2020
Q3 		$390K Sell
5,129
-1,141
-18% -$115K ﹤0.01% 518
2020
Q2 		$773K Buy
6,270
+132
+2% +$13.1K 0.01% 370
2020
Q1 		$519K Buy
6,138
+910
+17% +$78.4K 0.01% 400
2019
Q4 		$442K Sell
5,228
-1,549
-23% -$117K ﹤0.01% 497
2019
Q3 		$580K Sell
6,777
-150
-2% -$11.6K 0.01% 418
2019
Q2 		$593K Buy
6,927
+1,952
+39% +$167K 0.01% 414
2019
Q1 		$442K Buy
4,975
+47
+1% +$4.36K 0.01% 445
2018
Q4 		$420K Sell
4,928
-3,620
-42% -$344K 0.01% 435
2018
Q3 		$829K Buy
8,548
+190
+2% +$19K 0.01% 347
2018
Q2 		$787K Buy
8,358
+392
+5% +$34.3K 0.01% 356
2018
Q1 		$646K Buy
7,966
+4,382
+122% +$376K 0.01% 393
2017
Q4 		$320K Buy
+3,584
New +$312K ﹤0.01% 540

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Davenport & Co's BMRN Position: Q3 2023 in Review

Davenport & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 5,063 shares — an estimated $439K sold.

Davenport & Co first reported a position in BMRN in Q4 2017 and held it in 20 quarters. The position peaked at $829K in Q3 2018. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Davenport & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Davenport & Co sold 5,063 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $439K.
  • Davenport & Co first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 20 quarters.
  • Davenport & Co's BioMarin Pharmaceuticals position peaked at $829K in Q3 2018.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Davenport & Co's 13F filing for Q3 2023, filed 17 Oct 2023.